Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study Retraction in /10.3892/ol.2024.14360

Ishioka,Yoshiko; Tanaka,Hisashi; Makiguchi,Tomonori; Fujishima,Syunsuke; Nunomura,Yasuhito; Sakamoto,Hiroaki; Shiratori,Toshihiro; Taima,Kageaki; Tasaka,Sadatomo

doi:10.3892/ol.2023.14154

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study

Retraction in: /10.3892/ol.2024.14360

Authors:
- Yoshiko Ishioka
- Hisashi Tanaka
- Tomonori Makiguchi
- Syunsuke Fujishima
- Yasuhito Nunomura
- Hiroaki Sakamoto
- Toshihiro Shiratori
- Kageaki Taima
- Sadatomo Tasaka
View Affiliations

Affiliations: Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan
Published online on: November 16, 2023 https://doi.org/10.3892/ol.2023.14154
Article Number: 22
Copyright: © Ishioka et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Anamorelin, a ghrelin receptor agonist, is approved in Japan for the treatment of cachexia in patients with lung and gastrointestinal cancer. However, there is limited research on the usefulness of anamorelin in clinical settings, therefore, the present study evaluated its efficacy using patient characteristics. A total of 40 patients with non‑small cell lung cancer and cachexia who were prescribed anamorelin in the Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine (Aomori, Japan) between July 2021 and November 2022, were retrospectively assessed. Anamorelin was prescribed at a dose of 100 mg once daily to patients who had lost >5% of their body weight within 6 months. All patients were weighed before treatment and those who continued anamorelin treatment for 12 weeks were also weighed at 12 weeks. A logistic regression analysis was used to analyze the association between background characteristics and early discontinuation of treatment with anamorelin (within 4 weeks). The median age was 67 years (range, 36‑88), and 65% of the patients were male. There were 24 patients (60.0%) with an Eastern Cooperative Oncology Group Performance Status (ECOG‑PS) score 1, 11 patients (27.5%) with an ECOG‑PS score 2 and five patients (12.5%) with an ECOG‑PS score 3. The early discontinuation group included 11 patients (27.5%). An ECOG‑PS score ≥2 (odds ratio, 7.85; 95% confidence interval, 1.43‑43.21; P=0.018) was associated with early discontinuation. A total of 18/40 patients (45.0%) were able to continue anamorelin treatment for 12 weeks, and the mean change in body weight was +2.31 kg, which was a significant change from the weight recorded at baseline (P=0.027). The mean changes in lean body mass and soft lean mass between baseline and 12 weeks were +1.97 kg (P=0.14) and +1.26 kg (P=0.15), respectively. The results from the present study indicate that anamorelin is unlikely to be useful for patients with a poor general condition (ECOG‑PS score ≥2).

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar : PubMed/NCBI
3	Argilés JM, Busquets S, Stemmler B and López-Soriano FJ: Cancer cachexia: Understanding the molecular basis. Nat Rev Cancer. 14:754–762. 2014. View Article : Google Scholar : PubMed/NCBI
4	Ross PJ, Ashley S, Norton A, Priest K, Waters JS, Eisen T, Smith IE and O'Brien ME: Do patients with weight loss have a worse outcome when undergoing chemotherapy for lung cancers? Br J Cancer. 90:1905–1911. 2004. View Article : Google Scholar : PubMed/NCBI
5	Fearon KC, Voss AC and Hustead DS; Cancer Cachexia Study Group, : Definition of cancer cachexia: Effect of weight loss, reduced food intake, and systemic inflammation on functional status and prognosis. Am J Clin Nutr. 83:1345–1350. 2006. View Article : Google Scholar : PubMed/NCBI
6	Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol. 12:489–495. 2011. View Article : Google Scholar : PubMed/NCBI
7	Arends J, Strasser F, Gonella S, Solheim TS, Madeddu C, Ravasco P, Buonaccorso L, de van der Schueren MAE, Baldwin C, Chasen M, et al: Cancer cachexia in adult patients: ESMO clinical practice guidelines. ESMO Open. 6:1000922021. View Article : Google Scholar : PubMed/NCBI
8	Roeland EJ, Bohlke K, Baracos VE, Bruera E, Del Fabbro E, Dixon S, Fallon M, Herrstedt J, Lau H, Platek M, et al: Management of cancer cachexia: ASCO guideline. J Clin Oncol. 38:2438–2453. 2020. View Article : Google Scholar : PubMed/NCBI
9	Zhang H and Garcia JM: Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC. Expert Opin Pharmacother. 16:1245–1253. 2015. View Article : Google Scholar : PubMed/NCBI
10	Currow DC and Abernethy AP: Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome. Future Oncol. 10:789–802. 2014. View Article : Google Scholar : PubMed/NCBI
11	Pietra C, Takeda Y, Tazawa-Ogata N, Minami M, Yuanfeng X, Duus EM and Northrup R: Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: Preclinical profile. J Cachexia Sarcopenia Muscle. 5:329–337. 2014. View Article : Google Scholar : PubMed/NCBI
12	Delporte C: Structure and physiological actions of ghrelin. Scientifica. 2013:5189092013. View Article : Google Scholar : PubMed/NCBI
13	Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H and Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 402:656–660. 1999. View Article : Google Scholar : PubMed/NCBI
14	Neary NM, Small CJ, Wren AM, Lee JL, Druce MR, Palmieri C, Frost GS, Ghatei MA, Coombes RC and Bloom SR: Ghrelin increases energy intake in cancer patients with impaired appetite: Acute, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 89:2832–2836. 2004. View Article : Google Scholar : PubMed/NCBI
15	Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei MA and Bloom SR: Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 86:59922001. View Article : Google Scholar : PubMed/NCBI
16	Garcia JM, Friend J and Allen S: Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: A multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer. 21:129–137. 2013. View Article : Google Scholar : PubMed/NCBI
17	Garcia JM and Polvino WJ: Effect on body weight and safety of RC-1291, a novel, orally available ghrelin mimetic and growth hormone secretagogue: Results of a phase I, randomized, placebo-controlled, multiple-dose study in healthy volunteers. Oncologist. 12:594–600. 2007. View Article : Google Scholar : PubMed/NCBI
18	Garcia JM and Polvino WJ: Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res. 19:267–273. 2009. View Article : Google Scholar : PubMed/NCBI
19	Temel JS, Abernethy AP, Currow DC, Friend J, Duus EM, Yan Y and Fearon KC: Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): Results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 17:519–531. 2016. View Article : Google Scholar : PubMed/NCBI
20	Currow D, Temel JS, Abernethy A, Milanowski J, Friend J and Fearon KC: ROMANA 3: A phase 3 safety extension study of anamorelin in advanced non-small-cell lung cancer (NSCLC) patients with cachexia. Ann Oncol. 28:1949–1956. 2017. View Article : Google Scholar : PubMed/NCBI
21	Takayama K, Katakami N, Yokoyama T, Atagi S, Yoshimori K, Kagamu H, Saito H, Takiguchi Y, Aoe K, Koyama A, et al: Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: Results of a randomized phase 2 trial. Support Care Cancer. 24:3495–3505. 2016. View Article : Google Scholar : PubMed/NCBI
22	Katakami N, Uchino J, Yokoyama T, Naito T, Kondo M, Yamada K, Kitajima H, Yoshimori K, Sato K, Saito H, et al: Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer. 124:606–616. 2018. View Article : Google Scholar : PubMed/NCBI
23	Hamauchi S, Furuse J, Takano T, Munemoto Y, Furuya K, Baba H, Takeuchi M, Choda Y, Higashiguchi T, Naito T, et al: A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in advanced gastrointestinal cancer patients with cancer cachexia. Cancer. 125:4294–4302. 2019. View Article : Google Scholar : PubMed/NCBI
24	Wakabayashi H, Arai H and Inui A: The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer in Japan: Facts and numbers. J Cachexia Sarcopenia Muscle. 12:14–16. 2021. View Article : Google Scholar : PubMed/NCBI
25	Goldstraw P, Chansky K, Crowley J, Porta RR, Asamura H, Eberhardt WEE, Nicholson AG, Groome P, Mitchell A, Bolejack V, et al: The IASLC lung cancer staging project: Proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 11:39–51. 2016. View Article : Google Scholar : PubMed/NCBI
26	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
27	Freites-Martinez A, Santana N, Arias-Santiago S and Viera A: [Using the common terminology criteria for adverse events (CTCAE-version 5.0) to evaluate the severity of adverse events of anticancer therapies]. Actas Dermosifiliogr (Engl Ed). 112:90–92. 2021.(In English, Spanish). View Article : Google Scholar : PubMed/NCBI
28	Takayama K, Takiguchi T, Komura N and Naito T: Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study. Cancer Med. 12:2918–2928. 2023. View Article : Google Scholar : PubMed/NCBI
29	da Rocha IMG, Marcadenti A, de Medeiros GOC, Bezerra RA, Rego JFM, Gonzalez MC and Fayh APT: Affiliations expand is cachexia associated with chemotherapy toxicities in gastrointestinal cancer patients? A prospective study. J Cachexia Sarcopenia Muscle. 10:445–454. 2019. View Article : Google Scholar : PubMed/NCBI
30	Fujii H, Makiyama A, Iihara H, Okumura N, Yamamoto S, Imai T, Arakawa S, Kobayashi R, Tanaka Y, Yoshida K and Suzuki A: Cancer cachexia reduces the efficacy of nivolumab treatment in patients with advanced gastric cancer. Anticancer Res. 40:7067–7075. 2020. View Article : Google Scholar : PubMed/NCBI
31	Morimoto K, Uchino J, Yokoi T, Kijima T, Goto Y, Nakao A, Hibino M, Takeda T, Yamaguchi H, Takumi C, et al: Affiliations expand impact of cancer cachexia on the therapeutic outcome of combined chemoimmunotherapy in patients with non-small cell lung cancer: A retrospective study. Oncoimmunology. 10:19504112021. View Article : Google Scholar : PubMed/NCBI
32	Stene GB, Helbostad JL, Amundsen T, Sørhaug S, Hjelde H, Kaasa S and Grønberg BH: Changes in skeletal muscle mass during palliative chemotherapy in patients with advanced lung cancer. Acta Oncol. 54:340–348. 2015. View Article : Google Scholar : PubMed/NCBI
33	Antoun S, Birdsell L, Sawyer MB, Venner P, Escudier B and Baracos VE: Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: Results from a placebo-controlled study. J Clin Oncol. 28:1054–1060. 2010. View Article : Google Scholar : PubMed/NCBI
34	Vanhoutte G, van de Wiel M, Wouters K, Sels M, Bartolomeeussen L, De Keersmaecker S, Verschueren C, De Vroey V, De Wilde A, Smits E, et al: Cachexia in cancer: What is in the definition? BMJ Open Gastroenterol. 3:e0000972016. View Article : Google Scholar : PubMed/NCBI
35	Solheim TS, Laird BJA, Balstad TR, Stene GB, Bye A, Johns N, Pettersen CH, Fallon M, Fayers P, Fearon K and Kaasa S: A randomized phase II feasibility trial of a multimodal intervention for the management of cachexia in lung and pancreatic cancer. J Cachexia Sarcopenia Muscle. 8:778–788. 2017. View Article : Google Scholar : PubMed/NCBI
36	Naito T, Mitsunaga S, Miura S, Tatematsu N, Inano T, Mouri T, Tsuji T, Higashiguchi T, Inui A, Okayama T, et al: Feasibility of early multimodal interventions for elderly patients with advanced pancreatic and non-small-cell lung cancer. J Cachexia Sarcopenia Muscle. 10:73–83. 2019. View Article : Google Scholar : PubMed/NCBI
37	Miura S, Naito T, Mitsunaga S, Omae K, Mori K, Inano T, Yamaguchi T, Tatematsu N, Okayama T, Morikawa A, et al: A randomized phase II study of nutritional and exercise treatment for elderly patients with advanced non-small cell lung or pancreatic cancer: The NEXTAC-TWO study protocol. BMC Cancer. 19:5282019. View Article : Google Scholar : PubMed/NCBI